Cite
Hishida S, Kawakami K, Fujita Y, et al. Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer. Prostate. 2021;81(9):592-602doi: 10.1002/pros.24138.
Hishida, S., Kawakami, K., Fujita, Y., Kato, T., Takai, M., Iinuma, K., Nakane, K., Tsuchiya, T., Koie, T., Miura, Y., Ito, M., & Mizutani, K. (2021). Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer. The Prostate, 81(9), 592-602. https://doi.org/10.1002/pros.24138
Hishida, Seiji, et al. "Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer." The Prostate vol. 81,9 (2021): 592-602. doi: https://doi.org/10.1002/pros.24138
Hishida S, Kawakami K, Fujita Y, Kato T, Takai M, Iinuma K, Nakane K, Tsuchiya T, Koie T, Miura Y, Ito M, Mizutani K. Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer. Prostate. 2021 Jun;81(9):592-602. doi: 10.1002/pros.24138. Epub 2021 Apr 27. PMID: 33905554.
Copy
Download .nbib